UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 19, 2007
CELGENE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-16132 22-2711928
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
86 Morris Avenue, Summit, New Jersey 07901
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (908) 673-9000
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS
On June 19, 2007, Celgene Corporation announced that REVLIMID(R)
(lenalidomide) has been granted full marketing authorization by
the European Commission for use in combination with dexamethasone
as a treatment for patients with multiple myeloma who have
received at least one prior therapy. Multiple myeloma is the
second most commonly diagnosed blood cancer. According to the
International Myeloma Foundation, there are an estimated 750,000
people with multiple myeloma worldwide. There are more than 85,000
men and women in Europe currently undergoing treatment for
multiple myeloma, and 25,000 people are expected to die from this
blood cancer in 2007.
The Marketing Authorization Application (MAA) for REVLIMID(R) was
based upon the safety and efficacy results of two large,
randomized pivotal Phase III special protocol assessment trials,
North American Trial MM-009 and International Trial MM-010,
evaluating REVLIMID(R) plus dexamethasone in multiple myeloma
patients that have received at least one prior therapy.
Attached hereto and incorporated herein by reference as Exhibit
99.1 is the Press Release announcing such information.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibit 99.1 - Press Release dated June 19, 2007
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CELGENE CORPORATION
Date: June 19, 2007 By: /s/ Robert J. Hugin
--------------------------------------
Name: Robert J. Hugin
Title: President and
Chief Operating Officer